MAGL
Monoacylglycerol lipase (MAGL; EC 3.1.1.23) is the principal enzyme responsible for the in vivo degradation of 2-arachidonoyl glycerol (2-AG), an endogenous ligand of the cannabinoid receptors. Two other enzymes that participate in the breakdown of 2-AG are α/β-hydrolase domain-containing 6 (ABHD6) and α/β-hydrolase domain-containing 12 (ABHD12). It has been hypothesized that inhibition of MAGL may represent a useful and novel approach for the treatment of neuropathic pain, anxiety and inflammatory bowel diseases, vomiting, and nausea, as well as against the proliferation and migration of cancer cells[1].
[1] J.Z.Patel et al. Loratadine analogues as MAGL inhibitors. Bioorg Med Chem Lett. 2015 Apr 1;25(7):1436-42.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2696 | URB602 | Non-competitive inhibitor of MAGL | €60.00 | |
| 2580 | MJN110 | Potent, selective, and in-vivo-active MAGL inhibitor | €85.00 | |
| 2486 | JZP 361 | Selective reversible inhibitor of MAGL with Histamine H1 antagonistic activity | €125.00 | |
| 3000 | ABX-1431 | Highly potent, selective, brain-penetrant, and orally available MAGL inhibitor | €135.00 | |